Hopkins Will Study AIDS Drug

var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); ion" CONTENT="Researchers at Johns Hopkins University are beginning two studies that explore ways of extending the benefits of a life- prolonging medication called Bactrim to AIDS patients. Bactrim, a sulfa-based antibiotic, is used to prevent and treat pneumocystitis carinii pneumonia ( PCP ), an opportunistic infection that attack"> Hopkins Will Study AIDS Drug < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); > < > // var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www."); document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E")); >

Important note: Information in this article was accurate in 1994. The state of the art may have changed since the publication date.

Hopkins Will Study AIDS Drug

Baltimore Sun (12/27/94) P. 1B
Selby, Holly

Researchers at Johns Hopkins University are beginning two studies that explore ways of extending the benefits of a life- prolonging medication called Bactrim to AIDS patients. Bactrim, a sulfa-based antibiotic, is used to prevent and treat pneumocystitis carinii pneumonia (PCP), an opportunistic infection that attacks people with severely damaged immune systems. Unlike AZT, Bactrim is used to treat the complications that arise when the virus reaches an advanced stage. While many doctors call the drug the most broadly effective treatment available for people in the later stages of HIV infection, approximately half of the recipients cannot tolerate the medication. Manufactured by Roche Laboratories, Bactrim is the trade name for trimethoprim-sulfamethoxazole, which is also made by Burroughs Wellcome under the name Septra. The two studies will try to find alternatives to Bactrim and a method of building patients' tolerance to the drug.

941227
AD942307

Copyright © 1994 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 1994. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1994. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .